PTA-Adhoc: Dr. Hönle AG: Dr. Hönle AG adjusts outlook for 2021/2022 financial year
Public disclosure of inside information according to article 17 MAR
Gilching (pta028/22.07.2022/14:55) - Business development in the third quarter and especially in June 2022 was significantly worse than planned. The situation on procurement markets and the sharp increase in energy prices temporarily burden heavily on the Hönle Group's earnings. In addition, one-time effects affect the result. These are largely related to the personnel changes implemented at the management level of Dr. Hönle AG.
For the fourth quarter of the current financial year, the Executive Board does not expect any relaxation on the procurement markets and, in addition, a further increase in energy prices. Energy prices are significantly influenced by the Russia-Ukraine war and security of supply through the Nord Stream 1 gas pipeline.
This development has a strong impact on the profitability of Raesch Quarz (Germany) GmbH in particular, therefore the Board of Management expects a significant burden on earnings. The situation on the procurement markets will probably lead to a temporary burden on the gross profit margins in the fourth quarter and to orders having to be postponed.
In addition, the Hönle Group expects larger orders in the adhesives segment, which are likely to be postponed to the next financial year.
For the reasons mentioned above, the Executive Board is adjusting the sales forecast from previously €130 to €140 million to now € 125 to € 130 million (PY: €115 million) and the forecast for the operating result (EBIT) from previously € 14 to € 17 million to now € 9 to € 11 million (PY: € 0.3 million) for the Hönle Group in the 2021/2022 financial year.
The high order backlog of the Hönle Group and a large number of ongoing customer projects represent a good starting point for the new financial year. The burden on margins in the current financial year will probably be compensated in the financial year 2022/2023 due to sales price adjustments that have already taken place or are planned.
If the general economic conditions remain the same, increasing sales and earnings are therefore expected in the 2022/2023 financial year.
As planned, the 2021/2022 9-month statement will be published on August 5, 2022 and will then be available on the Internet at https://www.hoenle.com/investor-relation/financial-information.
Dr. Hönle AG is a listed technology company headquartered in Gilching, Germany. With its nearly 700 employees, the Hönle Group develops innovative solutions for a wide variety of industrial manufacturing processes. One focus of its activities is the development and sale of industrial adhesives and casting compounds. Moreover, the company manufactures equipment for ink and paint drying, adhesives and plastic curing as well as for air, water and surface disinfection and sunlight simulation. In addition, the corporate group produces UV lamps for disinfection and drying processes, among others, and manufactures tubes and semi-finished products made of quartz glass for use in various branches of industry. The Hönle Group supplies technology and world market leaders worldwide and is represented by its own entities and partner companies in more than 20 countries.
emitter: Dr. Hönle AG
address: Nicolaus-Otto-Str. 2, 82205 Gilching
contact person: Peter Weinert
phone: +49 8105 2083 173
ISIN(s): DE0005157101 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate